Monitoring Neural Tissues Properties by Modulated Imaging (MI) - Full Text View

Sponsor:	University of California, Irvine
Collaborator:	Beckman Laser Institute University of California Irvine
Information provided by:	University of California, Irvine
ClinicalTrials.gov Identifier:	NCT00555711

Purpose

We have developed a safe, non-contact, intra-operative guidance system to optimize tumor resection in neurosurgery. The Modulated Imaging (MI) is non-contact optical imaging technology developed at the Beckman Laser Institute, UCI.

Compared to other imaging approaches, MI has the unique capability of performing both diffuse optical tomography and rapid, wide-field quantitative mapping of tissue optical properties within a single measurement platform.

Preliminary in vivo studies have shown that brain tumors, infiltrating tumor margins and normal brain may have intrinsically different optical properties.

Condition
Brain Tumor

Study Type:	Observational
Study Design:	Case-Only, Cross-Sectional
Official Title:	Monitoring Neural Tissues Properties by Modulated Imaging (MI)

Resource links provided by NLM:

MedlinePlus related topics: Brain Cancer Cancer Childhood Brain Tumors

U.S. FDA Resources

Further study details as provided by University of California, Irvine:

Biospecimen Retention: None Retained

Biospecimen Description:

Estimated Enrollment:	70
Study Start Date:	November 2008
Estimated Study Completion Date:	July 2012
Estimated Primary Completion Date:	July 2012 (Final data collection date for primary outcome measure)

Detailed Description:

While compatible with time-modulation methods, MI alternatively uses spatially-modulated illumination for imaging of tissue constituents.

The MI system consists of

a light projection system that illuminates the tissue with spatial sinusoid patterns.
a CCD camera which collects the diffusely reflected light in a non-contact geometry. The wavelength of illumination can be selected by bandpass filtering of a broadband source,or by use of a monochromatic source.

Lastly, tissue fluorescence measurements can be performed by placing a combination of source-blocking and bandpass emission filters in front of the camera.

The diffusely reflected amplitude of the modulated wave carries both optical property (absorption, fluorescence, scattering) and depth information. Specifically, the sampling depth of the spatially-modulated wave is a function of the frequency of illumination and the tissue optical properties.

During neurosurgery when nervous tissue is exposed by the attending neurosurgeon, intraoperative pictures will be taken using the modulated imager (MI) by the investigators.

The imaging procedure may delay completion of the surgical case by an estimated 10 to 20 minutes. This is minimal prolongation considering most brain tumor resections take several hours.

The images acquired will be processed after the surgical procedure and will not be available to the surgeon during the operative procedure.

Eligibility

Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No
Sampling Method:	Non-Probability Sample

Study Population

primary care clinic

Criteria

Inclusion Criteria:

All nervous system tumor patients who undergo a preoperative MRI,and undergoing central nervous system operative procedures for non tumor.

Exclusion Criteria:

All emergency neurosurgical procedures.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00555711

Locations

United States, California
Neurosurgery department,University of California,Irvine
Orange, California, United States, 92868
Beckman Laser Institute,University of California,Irvine
Irvine, California, United States, 92612

Sponsors and Collaborators

University of California, Irvine

Beckman Laser Institute University of California Irvine

Investigators

Principal Investigator:	Mark Linskey, MD	Neurosurgery department,University of California,Irvine
Principal Investigator:	Bruce J Tromberg, PhD	Beckman Laser Institute University of California Irvine

More Information

No publications provided

Responsible Party:	Beckman Laser Institute ( Mark Linskey, MD )
Study ID Numbers:	LAMMP WIFI RR-01192-29
Study First Received:	November 7, 2007
Last Updated:	March 13, 2009
ClinicalTrials.gov Identifier:	NCT00555711 History of Changes
Health Authority:	United States: Institutional Review Board

Keywords provided by University of California, Irvine:

Brain tumor

Additional relevant MeSH terms:

Brain Neoplasms
Neoplasms
Neoplasms by Site
Nervous System Diseases

Central Nervous System Diseases
Central Nervous System Neoplasms
Brain Diseases
Nervous System Neoplasms

ClinicalTrials.gov processed this record on November 30, 2009